← Leaderboards
Steven Mark Albelda
University Of Pennsylvania
$22,046,338
Attributed
$22,046,338
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$50,652,527 · 16
By mechanism
P01$38,502,053 · 10
T32$7,323,663 · 1
R01$4,428,783 · 4
P50$398,028 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Timothy C Zhu$9,831,408
- Eli J Glatstein$647,800
- Keith A Cengel$851,559
- Joseph Stewart Friedberg$1,920,636
- Theresa M Busch$13,382,890
Others in their field
Top investigators on “Mesothelioma”
- Michael John Becich · University Of Pittsburgh At Pittsburgh$17,296,079
- Michele Carbone · University Of Hawaii At Manoa$10,761,809
- Joseph Robert Testa · Fox Chase Cancer Center$9,590,137
- Prasad S. Adusumilli · Sloan-Kettering Inst Can Research$7,394,083
- Raphael Bueno · Brigham And Women'S Hospital$6,320,859
- Harvey Ira Pass · New York University School Of Medicine$5,454,831
Research focus
MesotheliomaProgramsClinical TrialsTumorPreclinical StudyMalignant NeoplasmsCellsStructureMesothelinT-LymphocyteNovel StrategiesSafetyMalignant MesotheliomaTraffickingResearch PersonnelAnimal ModelImmuno-Gene TherapyChemotherapyAntigensPre-ClinicalImmuneT Cell TherapyMalignant Neoplasm Of ThoraxFuture
Grant awards (98)
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers$2,059,474
P01 · FY2022 · CA · contact PI
Project 2 - Preclinical studies: Overcoming tumor heterogeneity$505,053
P01 · FY2022 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$375,860
T32 · FY2022 · HL · contact PI
Core A - Administrative Core$126,834
P01 · FY2022 · CA · contact PI
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers$2,101,502
P01 · FY2021 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$517,115
T32 · FY2021 · HL · contact PI
Project 2 - Preclinical studies: Overcoming tumor heterogeneity$515,359
P01 · FY2021 · CA · contact PI
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells$368,288
R01 · FY2021 · CA · contact PI
Core A - Administrative Core$129,423
P01 · FY2021 · CA · contact PI
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers$2,101,502
P01 · FY2020 · CA · contact PI
Project 2 - Preclinical studies: Overcoming tumor heterogeneity$515,359
P01 · FY2020 · CA · contact PI
Training in Pulmonary Immunology$316,554
T32 · FY2020 · HL · contact PI
Core A - Administrative Core$129,423
P01 · FY2020 · CA · contact PI
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers$2,069,565
P01 · FY2019 · CA · contact PI
Project 2 - Preclinical studies: Overcoming tumor heterogeneity$504,690
P01 · FY2019 · CA · contact PI
Training in Pulmonary Immunology$475,170
T32 · FY2019 · HL · contact PI
Core A - Administrative Core$118,755
P01 · FY2019 · CA · contact PI
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers$2,105,511
P01 · FY2018 · CA · contact PI
Project 2 - Preclinical studies: Overcoming tumor heterogeneity$519,368
P01 · FY2018 · CA · contact PI
Training in Pulmonary Immunology$458,503
T32 · FY2018 · HL · contact PI
Project 2: Evaluation and Augmentation of Anti-tumoral Immune Responses Induced b$182,172
P01 · FY2018 · CA · contact PI
Core A - Administrative Core$129,423
P01 · FY2018 · CA · contact PI
Training in Pulmonary Immunology$444,999
T32 · FY2017 · HL · contact PI
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer$357,673
R01 · FY2017 · CA · contact PI
Project 2: Evaluation and Augmentation of Anti-tumoral Immune Responses Induced b$179,541
P01 · FY2017 · CA · contact PI
Immuno/Immuno-Gene Therapies for Thoracic Malignancies$1,182,811
P01 · FY2016 · CA · contact PI
Training in Pulmonary Immunology$438,104
T32 · FY2016 · HL · contact PI
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer$357,673
R01 · FY2016 · CA · contact PI
Preclinical Studies$352,395
P01 · FY2016 · CA · contact PI
Administration$130,455
P01 · FY2016 · CA · contact PI
Project 2: Evaluation and Augmentation of Anti-tumoral Immune Responses Induced b$90,861
P01 · FY2016 · CA · contact PI
Immuno/Immuno-Gene Therapies for Thoracic Malignancies$1,182,811
P01 · FY2015 · CA · contact PI
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer$357,673
R01 · FY2015 · CA · contact PI
Preclinical Studies$352,395
P01 · FY2015 · CA · contact PI
Project 2: Evaluation and Augmentation of Anti-tumoral Immune Responses Induced b$201,926
P01 · FY2015 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$197,484
T32 · FY2015 · HL · contact PI
Administration$130,455
P01 · FY2015 · CA · contact PI
Immuno/Immuno-Gene Therapies for Thoracic Malignancies$1,147,325
P01 · FY2014 · CA · contact PI
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer$346,942
R01 · FY2014 · CA · contact PI
Preclinical Studies$346,480
P01 · FY2014 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$246,258
T32 · FY2014 · HL · contact PI
Project 2: Evaluation and Augmentation of Anti-tumoral Immune Responses Induced b$203,801
P01 · FY2014 · CA · contact PI
Administration$124,541
P01 · FY2014 · CA · contact PI
Immuno/Immuno-Gene Therapies for Thoracic Malignancies$1,111,842
P01 · FY2013 · CA · contact PI
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer$357,673
R01 · FY2013 · CA · contact PI
Preclinical Studies$340,566
P01 · FY2013 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$334,699
T32 · FY2013 · HL · contact PI
Administration$118,627
P01 · FY2013 · CA · contact PI
Immuno/Immuno-Gene Therapies for Thoracic Malignancies$1,182,811
P01 · FY2012 · CA · contact PI
Preclinical Studies$352,394
P01 · FY2012 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$334,699
T32 · FY2012 · HL · contact PI
Administration$130,455
P01 · FY2012 · CA · contact PI
TRAINING IN PULMONARY IMMUNOLOGY$329,742
T32 · FY2011 · HL · contact PI
Immuno/Immunogene Therapies for Thoracic Malignancies$1,182,811
P01 · FY2010 · CA · contact PI
Preclinical Studies$299,585
P01 · FY2010 · CA · contact PI
Training in Pulmonary Immunology$150,359
T32 · FY2010 · HL · contact PI
Immuno/Immunogene Therapies for Thoracic Malignancies$1,203,367
P01 · FY2009 · CA · contact PI
Genetic Influence on Incidence of Acute Lung Injury$356,671
P01 · FY2009 · HL · contact PI
Preclinical Studies$291,984
P01 · FY2009 · CA · contact PI
Training in Pulmonary Immunology$205,892
T32 · FY2009 · HL · contact PI
Immuno/Immunogene Therapies for Thoracic Malignancies$1,200,734
P01 · FY2008 · CA · contact PI
Genetic Influence on Incidence of Acute Lung Injury$409,308
P01 · FY2008 · HL · contact PI
Preclinical Studies$286,715
P01 · FY2008 · CA · contact PI
Training in Pulmonary Immunology$270,290
T32 · FY2008 · HL · contact PI
Immuno/Immunogene Therapies for Thoracic Malignancies$1,181,405
P01 · FY2007 · CA · contact PI
Genetic Influence on Incidence of Acute Lung Injury$448,904
P01 · FY2007 · HL · contact PI
Preclinical Studies$291,494
P01 · FY2007 · CA · contact PI
Training in Pulmonary Immunology$278,766
T32 · FY2007 · HL · contact PI
Immuno/Immunogene Therapies for Thoracic Malignancies$1,173,204
P01 · FY2006 · CA · contact PI
Genetic Influence on Incidence of Acute Lung Injury$409,206
P01 · FY2006 · HL · contact PI
Training in Pulmonary Immunology$283,893
T32 · FY2006 · HL · contact PI
Preclinical Studies$169,633
P01 · FY2006 · CA · contact PI
Administration$81,029
P01 · FY2006 · CA · contact PI
Genetic Influence on Incidence of Acute Lung Injury$420,584
P01 · FY2005 · HL
The Role of PECAM in Models of Lung Injury$356,625
R01 · FY2005 · HL
GENE THERAPY FOR MALIGNANT MESOTHELIOMA$1,304,368
P01 · FY2004 · CA
The Role of PECAM in Models of Lung Injury$356,625
R01 · FY2004 · HL
Training in Pulmonary Immunology$127,603
T32 · FY2004 · HL
GENE THERAPY FOR MALIGNANT MESOTHELIOMA$1,288,670
P01 · FY2003 · CA
The Role of PECAM in Models of Lung Injury$356,625
R01 · FY2003 · HL
TRAINING IN PULMONARY IMMUNOLOGY$221,344
T32 · FY2003 · HL
GENE THERAPY FOR MALIGNANT MESOTHELIOMA$1,304,371
P01 · FY2002 · CA
TRAINING IN PULMONARY IMMUNOLOGY$457,412
T32 · FY2002 · HL
The Role of PECAM in Models of Lung Injury$356,625
R01 · FY2002 · HL
PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION$291,988
R01 · FY2002 · HL
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer$165,355
P50 · FY2002 · CA
VECTOR DEVELOPMENT /PRECLINICAL TESTING$0
P01 · FY2002 · CA
GENE THERAPY FOR MALIGNANT MESOTHELIOMA$1,293,872
P01 · FY2001 · CA
TRAINING IN PULMONARY IMMUNOLOGY$458,445
T32 · FY2001 · HL
PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION$285,388
R01 · FY2001 · HL
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer$165,355
P50 · FY2001 · CA
VECTOR DEVELOPMENT /PRECLINICAL TESTING$0
P01 · FY2001 · CA
GENE THERAPY FOR MALIGNANT MESOTHELIOMA$1,228,233
P01 · FY2000 · CA
TRAINING IN PULMONARY IMMUNOLOGY$400,472
T32 · FY2000 · HL
PECAM AND CALCIUM SIGNALING AND TRANSMIGRATION$278,985
R01 · FY2000 · HL
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer$33,659
P50 · FY2000 · CA
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer$33,659
P50 · FY2000 · CA
VECTOR DEVELOPMENT /PRECLINICAL TESTING$0
P01 · FY2000 · CA